In contrast, although RSL3 and erastin were initially identified as cancer drugs selective for tumor cells bearing oncogenic RAS [35, 36], cellular responses to either drug were not associated with the mutational status of KRAS (Figs. 1C and S1A) [35]. This evidence concerns the gene KRAS and neoplasm.